Biophytis SA announced that it has submitted the application for Clinical Trial Authorization to initiate SARA-31, the first phase 3 study in sarcopenia, on the European portal of the EMA.
Biophytis SA announced that it has submitted the application for Clinical Trial Authorization to initiate SARA-31, the first phase 3 study in sarcopenia, on the European portal of the EMA.